I think relative to genetic modification, it's ensuring that product approvals are timely and science-based and that they don't impede the use of those technologies.
Any time we develop a new technology, if industry can't use it to achieve those outcomes, we've lost, especially if other countries that are also exporting can use those technologies. That's an important differentiation. If technologies or animal health products are approved in one market and not another, that's a challenge for us.
I think that in terms of this, that's the biggest challenge we have, but we also have to keep ahead in developing those innovations to continue to help our industry as we move forward. We operate on costs at this point.